Compare NetApp Inc. (NTAP) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetApp Inc. vs Summit Therapeutics Inc — how do they compare? NetApp Inc. trades at $198.36 (market cap $38.95B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: NetApp Inc. is far larger — about 3.2× Summit Therapeutics Inc's market cap, and NetApp Inc. pays a 1.05% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| NTAP | SMMT | |
|---|---|---|
Market Cap | $38.95B | $12.06B |
Sector | Technology | Health |
52-Week High | $198.72 | $26.98 |
52-Week Low | $94.11 | $12.55 |
Enterprise Value | $38.10B | $11.39B |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NetApp (NTAP) trades at $202.00, up 1.65% today, near its 52-week high. The stock shows strong technical momentum with bullish moving averages and recent acquisitions like JetStream Software and DataPelago enhancing its AI infrastructure. Earnings have consistently beaten estimates, with Q1 2026 EPS of $2.43 surpassing the $2.27 forecast. Revenue grew to $6.57B in 2025, and profitability remains robust with an 18.43% net income margin.
Outlook is positive due to strategic AI investments and earnings momentum, but risks include high valuation multiples (P/E of 31.26) and competitive pressures. Analyst consensus is mixed, with 36.62% buy ratings, though the $170.73 price target suggests caution. Investors should weigh growth prospects against valuation concerns.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
